Montana Clinical Trials Report — June 2026

For Montanans considering participation in clinical research, June 2026 presents both urgent opportunities and exciting new avenues for contribution. With 8 clinical trials statewide slated to close within the next 90 days, time is of the essence for those interested in these specific areas of research. This includes a crucial opportunity for healthy volunteers, as 1 of these closing trials is still actively seeking participants without a specific health condition.

Individuals living with certain health challenges should particularly note the impending deadlines for trials focused on a range of conditions. These studies are nearing their enrollment capacity, and interested individuals should inquire promptly. Conditions with trials closing soon include:

• Castration-resistant prostate carcinoma
• Chronic granulomatous disease (CGD)
• COPD
• Delivery, obstetric
• Depression
• Maternal health
• Mental health
• Mental health services
• Metastatic malignant neoplasm in the bone
• Metastatic prostate carcinoma

Major New Research Initiatives Launch in Montana

This month, Montana welcomes 3 new clinical trials, marking an increase compared to the 1 trial that opened in May 2026. These new studies include significant Phase 3 drug trials from a major pharmaceutical sponsor, offering Montanans access to cutting-edge investigations for widespread health challenges like obesity and type 2 diabetes.

Leading the charge are two substantial Phase 3 drug trials sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. These trials are investigating aleniglipron, a promising new compound for weight management and metabolic health. These are global studies, and Montana's participation contributes to their broad impact:

• NCT07654361: "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)" is a pivotal, multicenter, global, randomized, placebo-controlled, double-blind study. This trial aims to enroll 3,600 participants worldwide to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily compared with placebo, when used in combination with a reduced-calorie diet.
• NCT07654374: "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)" is another randomized, double-blind, placebo-controlled study. This trial plans for 1,100 participants globally to assess the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in individuals living with overweight or obesity and type 2 diabetes mellitus.

These trials represent a significant investment in addressing metabolic health, a critical area of public health, and offer Montanans the chance to be at the forefront of developing new treatment options.

Expanding Opportunities for Health Conditions

The 3 new trials opening this month in Montana are all drug trials and primarily focus on metabolic health and eye conditions. The conditions addressed by these new studies include:

• Chronic weight management (2 trials)
• Obesity (2 trials)
• Overweight (2 trials)
• Dry eye disease (DED) (1 trial)
• Dry eye syndrome (DES) (1 trial)
• Type 2 diabetes mellitus (1 trial)

These new studies are exclusively drug trials, indicating a focus on testing novel pharmaceutical interventions. All 3 of these new trials are sponsored by industry, with Gasherbrum Bio, Inc. leading 2 and Vance Thompson Vision sponsoring the remaining 1.

Geographic Reach: Research Across the Big Sky Country

Montana's clinical research landscape continues to be active, with a total of 233 clinical trials currently recruiting across 18 cities and 121 research sites statewide. This broad distribution ensures that residents in various regions of Montana have access to cutting-edge research opportunities.

This month, the new research initiatives are concentrated in several key cities, expanding access to trials in different parts of the state:

• Missoula (2 new trials)
• Bozeman (1 new trial)
• Butte (1 new trial)

This geographic spread allows more Montanans to participate in studies without extensive travel, making clinical research more accessible to diverse communities across the state.

Participation and Eligibility: Healthy Volunteers and Older Adults

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 3 new trials launched this month, 1 is actively seeking healthy volunteers. Statewide, a total of 24 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and advancing healthcare.

Clinical trials in Montana are designed to be inclusive, with a broad range of eligibility criteria. All 3 of the new trials opened this month include older adults as potential participants, ensuring that research benefits this important demographic. There are no new trials specifically for children, or those exclusively for females or males this month.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 drug trials and the exploration of new treatments for metabolic health and other conditions, while also encouraging timely participation in studies nearing their conclusion across Montana.